Bacteriophage and Phage-Encoded Depolymerase Exhibit Antibacterial Activity Against K9-Type Acinetobacter baumannii

Alexander I Borzilov1, Nikolay V Volozhantsev1, Olga V Korobova1

  • 1State Research Center for Applied Microbiology and Biotechnology, City District Serpukhov, Moscow Region, 142279 Obolensk, Russia.

Viruses
|January 25, 2025
PubMed

Insights

A K9-specific phage and its depolymerase show significant therapeutic potential against Acinetobacter baumannii infections in mice, eradicating the pathogen in sepsis models and reducing bacterial load in skin infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Bacteriology

Background:

  • Acinetobacter baumannii is a significant nosocomial pathogen causing severe infections, especially in vulnerable populations.
  • The emergence of antibiotic resistance necessitates novel therapeutic strategies against A. baumannii.

Purpose of the Study:

  • To evaluate the in vivo therapeutic efficacy of the K9-specific virulent phage AM24 and its encoded depolymerase, DepAPK09.
  • To assess the stability and activity range of the phage and depolymerase under various conditions.

Main Methods:

  • In vivo mouse models were utilized, including sepsis and burn skin infection models.
  • Phage AM24 and recombinant DepAPK09 were administered for prevention, early treatment, and delayed treatment in sepsis models.
  • Bacterial load reduction was quantified in skin infection models.
  • Stability assays were performed across a range of temperatures and pH values.

Main Results:

  • A single administration of phage AM24 or DepAPK09 provided 100% protection in the mouse sepsis model when used for prevention or early treatment.
  • Delayed treatment with phage AM24 resulted in 70% survival, while DepAPK09 yielded 40% survival.
  • Both phage and depolymerase significantly reduced A. baumannii counts in burn wound skin infections.
  • The phage and depolymerase demonstrated high stability across diverse temperatures and pH levels.

Conclusions:

  • K9-specific phage AM24 and its depolymerase DepAPK09 exhibit potent in vivo therapeutic activity against A. baumannii.
  • These findings support the potential of phage therapy and depolymerases as alternative treatments for A. baumannii infections.
  • The stability of these agents suggests their suitability for a broad range of clinical applications.